Lucare Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 31-07-2024
- Paid Up Capital ₹ 1.85 Cr
as on 31-07-2024
- Company Age 16 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.75 Cr
as on 31-07-2024
- Satisfied Charges ₹ 3.50 M
as on 31-07-2024
- Revenue 122.29%
(FY 2023)
- Profit 5.83%
(FY 2023)
- Ebitda 1005.29%
(FY 2023)
- Net Worth 38.98%
(FY 2023)
- Total Assets 64.91%
(FY 2023)
About Lucare Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.85 Cr.
The company currently has active open charges totaling ₹3.75 Cr. The company has closed loans amounting to ₹3.50 M, as per Ministry of Corporate Affairs (MCA) records.
Bhola Agrawal, Anandita Agrawal, and Manishkant Agrawal serve as directors at the Company.
- CIN/LLPIN
U85110CT2008PTC020517
- Company No.
020517
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Jan 2008
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chhattisgarh
Industry
Company Details
- Location
Raipur, Chattisgarh, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Lucare Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anandita Agrawal  | Director | 04-Jul-2008 | Current |
| Bhola Agrawal | Director | 11-Feb-2008 | Current |
| Manishkant Agrawal | Director | 01-Dec-2008 | Current |
Financial Performance of Lucare Pharma.
Lucare Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 122.29% increase. The company also saw a slight improvement in profitability, with a 5.83% increase in profit. The company's net worth Soared by an impressive increase of 38.98%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lucare Pharma?
In 2023, Lucare Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 30 Oct 2023 | ₹1.75 Cr | Open |
Others Creation Date: 09 Aug 2023 | ₹2.00 Cr | Open |
Others Creation Date: 09 Aug 2018 | ₹3.50 M | Satisfied |
How Many Employees Work at Lucare Pharma?
Lucare Pharma has a workforce of 2 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lucare Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lucare Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
